BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 35706413)

  • 1. Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition.
    Alvarez-Breckenridge C; Markson SC; Stocking JH; Nayyar N; Lastrapes M; Strickland MR; Kim AE; de Sauvage M; Dahal A; Larson JM; Mora JL; Navia AW; Klein RH; Kuter BM; Gill CM; Bertalan M; Shaw B; Kaplan A; Subramanian M; Jain A; Kumar S; Danish H; White M; Shahid O; Pauken KE; Miller BC; Frederick DT; Hebert C; Shaw M; Martinez-Lage M; Frosch M; Wang N; Gerstner E; Nahed BV; Curry WT; Carter B; Cahill DP; Boland GM; Izar B; Davies MA; Sharpe AH; Suvà ML; Sullivan RJ; Brastianos PK; Carter SL
    Cancer Immunol Res; 2022 Aug; 10(8):996-1012. PubMed ID: 35706413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
    Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
    Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases.
    Fischer GM; Jalali A; Kircher DA; Lee WC; McQuade JL; Haydu LE; Joon AY; Reuben A; de Macedo MP; Carapeto FCL; Yang C; Srivastava A; Ambati CR; Sreekumar A; Hudgens CW; Knighton B; Deng W; Ferguson SD; Tawbi HA; Glitza IC; Gershenwald JE; Vashisht Gopal YN; Hwu P; Huse JT; Wargo JA; Futreal PA; Putluri N; Lazar AJ; DeBerardinis RJ; Marszalek JR; Zhang J; Holmen SL; Tetzlaff MT; Davies MA
    Cancer Discov; 2019 May; 9(5):628-645. PubMed ID: 30787016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Sequencing Radiation Therapy and Immune Checkpoint Inhibitors in the Treatment of Melanoma Brain Metastases.
    Pomeranz Krummel DA; Nasti TH; Izar B; Press RH; Xu M; Lowder L; Kallay L; Rupji M; Rosen H; Su J; Curran W; Olson J; Weinberg B; Schniederjan M; Neill S; Lawson D; Kowalski J; Khan MK; Sengupta S
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):157-163. PubMed ID: 32057994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of systemic therapy in melanoma brain metastases: a narrative review.
    Saleem K; Davar D
    Chin Clin Oncol; 2022 Jun; 11(3):24. PubMed ID: 35818856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA).
    Hassel JC; Schank TE; Smetak H; Mühlbauer J; Salzmann M; Machiraju D; Menzer C; Lang K; König L; Haefner MF; Hülsmeyer I; Kohler C; Spang R; Enk A; Debus J; Beckhove P
    Oncoimmunology; 2022; 11(1):2066609. PubMed ID: 35481285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases.
    Smalley I; Chen Z; Phadke M; Li J; Yu X; Wyatt C; Evernden B; Messina JL; Sarnaik A; Sondak VK; Zhang C; Law V; Tran N; Etame A; Macaulay RJB; Eroglu Z; Forsyth PA; Rodriguez PC; Chen YA; Smalley KSM
    Clin Cancer Res; 2021 Jul; 27(14):4109-4125. PubMed ID: 34035069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the systemic treatment of melanoma brain metastases.
    Glitza Oliva IC; Schvartsman G; Tawbi H
    Ann Oncol; 2018 Jul; 29(7):1509-1520. PubMed ID: 29790899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma.
    Schvartsman G; Ma J; Bassett RL; Haydu LE; Amaria RN; Hwu P; Wong MK; Hwu WJ; Diab A; Patel SP; Davies MA; Hamerschlak N; Tawbi HA; Glitza Oliva IC
    Cancer; 2019 Dec; 125(23):4193-4202. PubMed ID: 31398264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.
    Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single-center retrospective analysis of prognoses in patients with melanoma brain metastases and effectiveness of treatment in Japan.
    Wada S; Ogata D; Kashihara T; Okuma K; Eto H; Nakano E; Takahashi A; Namikawa K; Igaki H; Yamazaki N
    Cancer Med; 2023 Dec; 12(24):21933-21943. PubMed ID: 38083908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissecting the treatment-naive ecosystem of human melanoma brain metastasis.
    Biermann J; Melms JC; Amin AD; Wang Y; Caprio LA; Karz A; Tagore S; Barrera I; Ibarra-Arellano MA; Andreatta M; Fullerton BT; Gretarsson KH; Sahu V; Mangipudy VS; Nguyen TTT; Nair A; Rogava M; Ho P; Koch PD; Banu M; Humala N; Mahajan A; Walsh ZH; Shah SB; Vaccaro DH; Caldwell B; Mu M; Wünnemann F; Chazotte M; Berhe S; Luoma AM; Driver J; Ingham M; Khan SA; Rapisuwon S; Slingluff CL; Eigentler T; Röcken M; Carvajal R; Atkins MB; Davies MA; Agustinus A; Bakhoum SF; Azizi E; Siegelin M; Lu C; Carmona SJ; Hibshoosh H; Ribas A; Canoll P; Bruce JN; Bi WL; Agrawal P; Schapiro D; Hernando E; Macosko EZ; Chen F; Schwartz GK; Izar B
    Cell; 2022 Jul; 185(14):2591-2608.e30. PubMed ID: 35803246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MET receptor serves as a promising target in melanoma brain metastases.
    Redmer T; Schumann E; Peters K; Weidemeier ME; Nowak S; Schroeder HWS; Vidal A; Radbruch H; Lehmann A; Kreuzer-Redmer S; Jürchott K; Radke J
    Acta Neuropathol; 2024 Feb; 147(1):44. PubMed ID: 38386085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies.
    Bander ED; Yuan M; Carnevale JA; Reiner AS; Panageas KS; Postow MA; Tabar V; Moss NS
    Cancer; 2021 Jun; 127(12):2062-2073. PubMed ID: 33651913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recommended first-line management of brain metastases from melanoma: A multicenter survey of clinical practice.
    Jablonska PA; Fong CH; Kruser T; Weiss J; Liu ZA; Takami H; Narita Y; Ynoe de Moraes F; Dasgupta A; Ong CK; Yang JCH; Lee JH; Pavlakis N; Kongkham P; Butler M; Shultz DB
    Radiother Oncol; 2022 Mar; 168():89-94. PubMed ID: 35121033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
    Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M
    Front Immunol; 2021; 12():799455. PubMed ID: 35069581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).
    Lau PKH; Feran B; Smith L; Lasocki A; Molania R; Smith K; Weppler A; Angel C; Kee D; Bhave P; Lee B; Young RJ; Iravani A; Yeang HA; Vergara IA; Kok D; Drummond K; Neeson PJ; Sheppard KE; Papenfuss T; Solomon BJ; Sandhu S; McArthur GA
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities.
    Karz A; Dimitrova M; Kleffman K; Alvarez-Breckenridge C; Atkins MB; Boire A; Bosenberg M; Brastianos P; Cahill DP; Chen Q; Ferguson S; Forsyth P; Glitza Oliva IC; Goldberg SB; Holmen SL; Knisely JPS; Merlino G; Nguyen DX; Pacold ME; Perez-Guijarro E; Smalley KSM; Tawbi HA; Wen PY; Davies MA; Kluger HM; Mehnert JM; Hernando E
    Pigment Cell Melanoma Res; 2022 Nov; 35(6):554-572. PubMed ID: 35912544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.
    Sloot S; Chen YA; Zhao X; Weber JL; Benedict JJ; Mulé JJ; Smalley KS; Weber JS; Zager JS; Forsyth PA; Sondak VK; Gibney GT
    Cancer; 2018 Jan; 124(2):297-305. PubMed ID: 29023643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of immunotherapy for melanoma brain metastases in patients with concurrent corticosteroid exposure.
    Tringale KR; Reiner AS; Sehgal RR; Panageas K; Betof Warner AS; Postow MA; Moss NS
    CNS Oncol; 2023 Mar; 12(1):CNS93. PubMed ID: 36802833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.